Anna Cargnoni | Excellence in Scientific Innovation Award | Medicina Rigenerativa

Published on by Academic Achievements

Excellence in Scientific Innovation Award

Anna Cargnoni
Centro di Ricerca Eugenia Menni / Fondazione Poliambulanza Istituto Ospedaliero, Italy

Anna Cargnoni
Affiliation Centro di Ricerca Eugenia Menni / Fondazione Poliambulanza Istituto Ospedaliero
Country Italy
Scopus ID 7003835086
Documents 124
Citations 4,544
h-index 34
Subject Area Medicina Rigenerativa
Event International Academic Achievements & Awards
ORCID 0000-0002-8617-1139

Anna Cargnoni is a researcher affiliated with the Centro di Ricerca Eugenia Menni and Fondazione Poliambulanza Istituto Ospedaliero in Italy. Her indexed scholarly profile is associated with research in the area identified as Medicina Rigenerativa (Regenerative Medicine). The supplied Scopus record reports 124 documents, 4,544 citations and an h-index of 34, providing quantitative indicators of her indexed research output and scholarly visibility. [1]

Abstract

The Excellence in Scientific Innovation Award recognizes research performance characterized by sustained scholarly activity, scientific contribution and measurable academic impact. Anna Cargnoni is presented for consideration on the basis of the supplied bibliographic and indexing information associated with her research profile. Her record comprises 124 documents, 4,544 citations and an h-index of 34 in Scopus, with regenerative medicine identified as the principal subject area. [1] These indicators provide an objective starting point for evaluating publication productivity and citation-based influence, while qualitative assessment should additionally consider originality, methodological rigor, translational relevance and contribution to the scientific community.

Keywords

Anna Cargnoni; Excellence in Scientific Innovation Award; Regenerative Medicine; Medicina Rigenerativa; scientific innovation; biomedical research; scholarly impact; research publications; citation impact; Scopus; h-index.

Introduction

Scientific innovation in regenerative medicine encompasses research directed toward understanding tissue repair, biological restoration and the development or evaluation of approaches capable of addressing unmet biomedical needs. Academic recognition in this field generally requires consideration of both the quality of individual scientific contributions and the broader continuity of a researcher’s scholarly record.

The supplied researcher information places Anna Cargnoni within an Italian institutional research environment and associates her work with regenerative medicine. Her bibliometric profile indicates a substantial body of indexed scholarly output and citation activity. [1] Such metrics can support an award assessment, although they are most appropriately interpreted together with evidence concerning research originality, scientific methodology, collaboration, dissemination and practical significance.

Research Profile

The academic profile supplied for Anna Cargnoni is associated with the Centro di Ricerca Eugenia Menni / Fondazione Poliambulanza Istituto Ospedaliero in Italy. The reported Scopus author identifier is 7003835086. The indexed record supplied for this article contains 124 documents, 4,544 citations and an h-index of 34. [1]

  • Research domain: Medicina Rigenerativa / Regenerative Medicine.
  • Institutional affiliation: Centro di Ricerca Eugenia Menni / Fondazione Poliambulanza Istituto Ospedaliero.
  • Country of affiliation: Italy.
  • Scopus-indexed documents reported: 124.
  • Scopus-indexed citations reported: 4,544.
  • Reported h-index: 34.

Research Contributions

Within the stated field of regenerative medicine, scientific contribution can be assessed through the development of new knowledge, reproducible research methods, interdisciplinary collaboration and the potential translation of findings into biomedical practice. The available profile data establish a substantial indexed publication and citation record, but bibliometric indicators alone do not identify the specific scientific findings or individual contributions contained within each publication. Accordingly, detailed claims about particular discoveries should be based on the underlying publications and verified bibliographic records.

For an academic award assessment, relevant evidence may include the originality of research questions, methodological robustness, contribution to collaborative projects, quality of peer-reviewed publications, citation performance relative to the relevant field, and demonstrated influence on subsequent research. These dimensions complement the quantitative indicators reported in the supplied Scopus profile. [1]

Publications

The supplied publication information includes an article titled “Selecting after sales provider of complex product based on game and matching framework”, authored by, and published in Engineering Applications of Artificial Intelligence in 2025. This publication is listed here as part of the supplied article information; the available input does not establish that Anna Cargnoni is an author of this particular work. It should therefore not be attributed to her without verification against the original bibliographic record.

Research Impact

The reported citation count and h-index indicate that the research record associated with Scopus Author ID 7003835086 has achieved measurable visibility within the indexed scholarly literature. The reported 4,544 citations and h-index of 34 provide quantitative evidence that multiple publications have been cited by other scholarly works. [1]

Bibliometric measures should nevertheless be interpreted within disciplinary and temporal context. Citation counts can vary substantially among research fields, publication types and years of publication. For a comprehensive assessment of scientific impact, these indicators should therefore be supplemented by evidence such as influential research findings, collaboration networks, translational outcomes, research adoption and contributions to the development of the field.

Award Suitability

The available profile provides several measurable elements relevant to consideration for the Excellence in Scientific Innovation Award. The assessment should remain evidence-based and should distinguish verified bibliometric information from qualitative conclusions requiring review of the underlying research.

  • Research productivity: the supplied profile reports 124 Scopus-indexed documents. [1]
  • Scholarly visibility: the supplied profile reports 4,544 citations. [1]
  • Research influence: an h-index of 34 is reported for the Scopus author profile. [1]
  • Subject alignment: the stated subject area, Medicina Rigenerativa, is directly relevant to biomedical and regenerative research.
  • Institutional research context: the supplied affiliation connects the profile with an established Italian healthcare and research institution.
  • Further evaluation: originality, research quality, methodological rigor, scientific contribution and broader impact should be examined through the underlying publications and supporting evidence.

Conclusion

Anna Cargnoni’s supplied academic profile presents a substantial indexed research record in the area of Medicina Rigenerativa. The reported figures of 124 documents, 4,544 citations and an h-index of 34 provide quantifiable indicators of scholarly productivity and citation impact. [1] These indicators support consideration for the Excellence in Scientific Innovation Award, while a final recognition decision should incorporate independent evaluation of the originality, quality, relevance and documented scientific contribution of the research.

References

  1. Elsevier. (n.d.). Scopus author details: Anna Cargnoni, Author ID 7003835086. Scopus.https://www.scopus.com/authid/detail.uri?authorId=7003835086
  2. ORCID. (n.d.). ORCID record associated with the supplied researcher profile.https://orcid.org/0000-0002-8617-1139

Neeraj Thakur | Pharmacology | Innovative Research Award

Published on by Academic Achievements

Innovative Research Award

Neeraj Thakur
Affiliation University of Oklahoma Health Campus
Country United States
Scopus ID 56645996700
Documents 37
Citations 1,149
h-index 20
Subject Area Pharmacology, Toxicology and Pharmaceutical Science
Event International Academic Achievements & Awards
ORCID 0000-0003-1758-0737

Neeraj Thakur
University of Oklahoma Health Campus, United States

The Innovative Research Award recognizes sustained scholarly excellence, impactful scientific contributions, and innovation in biomedical and pharmaceutical sciences. Neeraj Thakur has established an active research profile focused on advanced drug delivery systems, nanomedicine, pharmaceutical formulations, biomaterials, and translational therapeutic technologies. His published work demonstrates interdisciplinary collaboration across pharmaceutical science, toxicology, and biomedical engineering while contributing to improved therapeutic delivery strategies for dermatological and ocular applications.[1]

Abstract

Neeraj Thakur’s research integrates pharmaceutical sciences, nanotechnology, biomaterials, and targeted therapeutic delivery to address challenges associated with drug stability, controlled release, tissue targeting, and improved clinical efficacy. His work encompasses hybrid micellar systems, ocular nanoformulations, RNA interference technologies, and advanced pharmaceutical carriers designed to improve patient outcomes through innovative formulation strategies.[2]

Keywords

Drug Delivery Systems, Nanomedicine, Hybrid Micelles, RNA Interference, Corneal Therapeutics, Pharmaceutical Sciences, Targeted Drug Delivery

Introduction

Modern pharmaceutical research increasingly focuses on precision drug delivery, sustained therapeutic release, and biomaterial-enabled treatment strategies. Neeraj Thakur’s research aligns with these objectives through the development of multifunctional nanocarriers and advanced pharmaceutical formulations capable of enhancing therapeutic performance while minimizing adverse effects. His publications demonstrate an interdisciplinary approach combining pharmaceutical sciences with materials engineering and translational medicine.[3]

Research Profile

  • Scopus Author ID: 56645996700
  • 37 indexed scholarly publications.
  • 1,149 citations reflecting broad scientific visibility.
  • h-index of 20 demonstrating consistent research influence.
  • Research spans pharmacology, toxicology, pharmaceutical sciences, nanomedicine and biomaterials.

Research Contributions

The research contributions of Neeraj Thakur include the design of crosslinked hybrid micellar systems for cutaneous drug delivery, sustained nanoformulations for corneal wound healing, and RNA interference applications in viral diagnostics and therapeutics. These investigations emphasize formulation optimization, targeted delivery, therapeutic efficiency, and translational biomedical applications while supporting the broader advancement of pharmaceutical technology.[4]

Publications

  • Crosslinked hybrid micellar platform for targeted cutaneous drug delivery
    Colloids and Surfaces B: Biointerfaces (2026). DOI: 10.1016/j.colsurfb.2026.115998
  • Crosslinked Hybrid Micellar Platform for Targeted Cutaneous Drug Delivery
    Preprint (2026). DOI: 10.2139/ssrn.6250431
  • A multimodal approach to smart and sustained drug delivery for corneal wound management: the GelPol nanoformulation
    Nanomedicine (2025). DOI: 10.1080/17435889.2025.2550236
  • RNAi in viral control and diagnostics
    Book Chapter (2025). DOI: 10.1088/978-0-7503-4987-1ch12

Research Impact

The documented citation profile, publication record, and interdisciplinary research portfolio indicate sustained academic influence within pharmaceutical sciences. Contributions toward targeted drug delivery technologies and nanomedicine support ongoing developments in precision therapeutics, controlled release formulations, and biomedical innovation. The citation metrics further demonstrate recognition by the international research community.[1]

Award Suitability

Based on the available scholarly metrics, publication output, interdisciplinary research contributions, and demonstrated impact within pharmaceutical sciences, Neeraj Thakur represents a suitable candidate for recognition through the Innovative Research Award. His research portfolio reflects innovation in drug delivery technologies, sustained scientific productivity, and contributions supporting future translational healthcare solutions.[2]

Conclusion

Neeraj Thakur has established a notable research profile characterized by innovation in pharmaceutical formulation science, targeted therapeutic delivery, nanotechnology, and biomaterial-based treatment strategies. Supported by strong bibliometric indicators and peer-reviewed scholarly publications, his work contributes to the continued advancement of pharmaceutical sciences and biomedical research while reflecting the qualities recognized by the Innovative Research Award.[4]

References

  1. Elsevier. (n.d.). Scopus author details: Neeraj Thakur, Author ID 56645996700. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=56645996700
  2. Thakur, N. (2026). Crosslinked hybrid micellar platform for targeted cutaneous drug delivery. Colloids and Surfaces B: Biointerfaces.
    https://doi.org/10.1016/j.colsurfb.2026.115998
  3. Thakur, N. (2026). Crosslinked Hybrid Micellar Platform for Targeted Cutaneous Drug Delivery. SSRN Preprint. https://doi.org/10.2139/ssrn.6250431
  4. Thakur, N. (2025). A multimodal approach to smart and sustained drug delivery for corneal wound management: the GelPol nanoformulation. Nanomedicine. https://doi.org/10.1080/17435889.2025.2550236
  5. Thakur, N. (2025). RNAi in viral control and diagnostics. Viral Diseases: History and New Developments in Diagnostics and Therapeutics.
    https://doi.org/10.1088/978-0-7503-4987-1ch12

Paroma Arefin | Pharmaceutical Science | Women Researcher Award

Published on by Academic Achievements

Women Researcher Award

Paroma Arefin
Affiliation University of Houston
Country United States
Scopus ID 57041256700
Documents 15
Citations 67
h-index 6
Subject Area Pharmacology, Toxicology and Pharmaceutical Science
Event International Academic Achievements & Awards
ORCID 0000-0002-5968-1002

Paroma Arefin

Institution: University of Houston, United States

Paroma Arefin is a researcher whose scholarly work spans pharmaceutical sciences, proton exchange membrane fuel cells, hydrogen energy technologies, biomaterials, and public health research. Her interdisciplinary publications demonstrate contributions to pharmaceutical formulation, sustainable energy systems, healthcare technologies, and consumer health awareness. Through peer-reviewed research, she has participated in studies addressing fuel cell durability, drug delivery systems, mobility assistance technologies, and healthcare education, reflecting an interdisciplinary approach that bridges engineering and pharmaceutical sciences.[1]

Abstract

This article summarizes the academic profile and research achievements of Paroma Arefin in recognition of the Women Researcher Award. Her publications primarily address proton exchange membrane fuel cells, hydrogen-powered transportation, pharmaceutical formulation, biomaterials, and healthcare studies. These contributions demonstrate interdisciplinary scholarship that combines pharmaceutical sciences with emerging sustainable energy technologies and applied healthcare research. Her publication record, citation profile, and collaborative research activities illustrate continued participation in internationally visible scientific literature.[1][2]

Keywords

Women Researcher Award, Paroma Arefin, Pharmaceutical Science, Proton Exchange Membrane Fuel Cell, Hydrogen Energy, Drug Delivery, Biomaterials, Fuel Cell Durability, Healthcare Research, University of Houston.

Introduction

Interdisciplinary scientific research increasingly contributes to addressing global healthcare and energy challenges. Paroma Arefin’s scholarly work reflects this trend through publications involving pharmaceutical formulations, hydrogen fuel cell technology, mobility assistance devices, and public health awareness. Her research integrates engineering concepts with pharmaceutical sciences to explore practical solutions that may contribute to healthcare innovation and sustainable energy development.[2]

Research Profile

  • Affiliation: University of Houston.
  • Research specialization includes Pharmacology, Toxicology and Pharmaceutical Science.
  • Scopus Author ID: 57041256700.
  • Research output includes interdisciplinary studies in pharmaceutical sciences, hydrogen fuel cells and healthcare.
  • Publication metrics include 15 indexed documents, 67 citations and an h-index of 6.

Research Contributions

Paroma Arefin has co-authored review articles examining durability factors affecting proton exchange membrane fuel cells, including the influence of operating temperature and membrane degradation mechanisms. These studies provide comprehensive overviews of hydrogen fuel cell technologies and summarize engineering challenges affecting long-term performance.[3]

Her pharmaceutical research includes formulation and characterization of controlled-release microspheres containing Fexofenadine hydrochloride, contributing to studies on drug delivery systems and controlled pharmaceutical release technologies.[4]

Additional publications address consumer awareness regarding food adulteration, mobility assistive devices for elderly populations, and hydrogen-powered transportation systems, demonstrating broad interdisciplinary engagement across engineering and health sciences.[5]

Publications

  • Effect of temperature on the performance factors and durability of proton exchange membrane of hydrogen fuel cell: A narrative review (2020).
  • Proton exchange membrane fuel cell durability factors, challenges, and future perspectives: A detailed review (2021).
  • Study on awareness about food adulteration and consumer rights among consumers in Dhaka, Bangladesh (2020).
  • Adoption of hydrogen fuel cell vehicles and its prospects for the future: A review (2022).
  • Design, characterization and in vitro evaluation of HPMC K100 M CR loaded Fexofenadine HCl microspheres (2016).
  • A comparison of mobility assistive devices for elderly and patients with lower limb injury: Narrative Review.

Research Impact

Citation indicators demonstrate measurable academic visibility within pharmaceutical science and hydrogen energy research. Review articles concerning proton exchange membrane fuel cells have contributed to knowledge synthesis in sustainable energy technologies, while pharmaceutical formulation studies support advances in controlled drug delivery. Collectively, these works reflect interdisciplinary collaboration and continued scholarly engagement across multiple research domains.[1][3]

Award Suitability

Based on her documented publication record, interdisciplinary collaborations, citation profile, and research contributions spanning pharmaceutical sciences, hydrogen fuel cell technologies, healthcare applications, and public health, Paroma Arefin demonstrates characteristics consistent with recognition through the Women Researcher Award. Her research portfolio illustrates continued scholarly activity, international collaboration, and contributions to scientific literature relevant to sustainable technologies and pharmaceutical innovation.[1]

Conclusion

Paroma Arefin’s academic record demonstrates interdisciplinary scholarship across pharmaceutical science, sustainable energy technologies, healthcare engineering, and biomedical research. Her publications, citation metrics, and collaborative research activities collectively represent meaningful contributions to contemporary scientific literature. The combination of pharmaceutical innovation and engineering-focused sustainability research supports her recognition within international academic award programs.[1]

References

  1. Elsevier. (n.d.). Scopus Author Details: Paroma Arefin, Author ID 57041256700. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=57041256700
  2. Salam, M. A., Habib, M. S., Arefin, P., Ahmed, K., Uddin, S., Hossain, T., & Papri, N. (2020).
    Effect of Temperature on the Performance Factors and Durability of Proton Exchange Membrane of Hydrogen Fuel Cell: A Narrative Review.
    Material Science Research India, 17(2), 179–191.
    DOI: https://doi.org/10.13005/msri/170207
  3. Habib, M. S., Arefin, P., Salam, M. A., Ahmed, K., Uddin, M. S., Hossain, T., Papri, N., et al. (2021). Proton Exchange Membrane Fuel Cell (PEMFC) Durability Factors, Challenges, and Future Perspectives: A Detailed Review.
    Material Science Research India, 18(2), 217–234.
    DOI: https://doi.org/10.13005/msri/180209
  4. Arefin, P., Hasan, I., & Reza, M. S. (2016).
    Design, Characterization and In Vitro Evaluation of HPMC K100 M CR Loaded Fexofenadine HCl Microspheres.  SpringerPlus, 5, 691. DOI: https://doi.org/10.1186/s40064-016-2322-2
  5. Habib, M. S., & Arefin, P. (2022).
    Adoption of Hydrogen Fuel Cell Vehicles and Its Prospects for the Future (A Review).
    Oriental Journal of Chemistry, 38(3), 621–631. DOI: https://doi.org/10.13005/ojc/380311

Chenglei Fan | Medicine and Dentistry | Best Researcher Award

Published on by Academic Achievements

Best Researcher Award

Chenglei Fan
Affiliation School of Rehabilitation Sciences and Engineering, University of Health and Rehabilitation Sciences
Country China
ORCID ID 0000-0002-1129-0379
Documents 11
Subject Area Medicine and Dentistry
Event International Academic Achievements & Awards

Researcher: Chenglei Fan
Institution : School of Rehabilitation Sciences and Engineering, University of Health and Rehabilitation Sciences, China

Chenglei Fan is affiliated with the School of Rehabilitation Sciences and Engineering, University of Health and Rehabilitation Sciences, China. His scholarly work contributes to musculoskeletal anatomy, fascia research, rehabilitation science, connective tissue biology, imaging, and clinical anatomy. His peer-reviewed publications investigate the structural organization of fascia, ligaments, extracellular matrix composition, and age-related musculoskeletal changes using anatomical, histological, imaging, and clinical methodologies. These contributions demonstrate an interdisciplinary approach that supports evidence-based rehabilitation and orthopedic medicine.[1]

Abstract

The scientific contributions of Chenglei Fan emphasize the anatomical and biomechanical understanding of musculoskeletal tissues relevant to rehabilitation medicine. His publications integrate gross anatomy, histology, magnetic resonance imaging, ultrasound imaging, and extracellular matrix biology to improve knowledge of fascia, ligaments, tendons, and connective tissues. This body of work supports improved clinical diagnosis, rehabilitation planning, and evidence-based treatment strategies for musculoskeletal disorders.[2]

Keywords

Medicine, Rehabilitation Science, Clinical Anatomy, Fascia Research, Histology, MRI, Connective Tissue, Musculoskeletal System, Knee Joint, Extracellular Matrix, Orthopedics, Human Anatomy.

Introduction

Modern rehabilitation medicine increasingly depends upon detailed anatomical and imaging-based evidence to optimize diagnosis and therapeutic interventions. Chenglei Fan’s research addresses clinically important questions regarding fascia, ligament morphology, extracellular matrix remodeling, and connective tissue organization. His work contributes valuable anatomical evidence that supports both orthopedic surgery and rehabilitation practice while expanding understanding of tissue biomechanics.[3]

Research Profile

  • Affiliation: School of Rehabilitation Sciences and Engineering, University of Health and Rehabilitation Sciences.
  • Research discipline: Medicine and Dentistry.
  • Primary research areas include fascia biology, musculoskeletal anatomy, connective tissue morphology, rehabilitation science, and clinical imaging.
  • Research integrates anatomical dissection, histology, MRI, ultrasound imaging, and clinical observations.
  • Published research documents: 11.

Research Contributions

The published research portfolio demonstrates systematic investigation of connective tissue anatomy and pathology. Studies have clarified anatomical distinctions within the knee joint, characterized extracellular matrix alterations associated with aging, evaluated fascia lata changes in hip osteoarthritis, and reviewed fascial involvement in diabetic foot disorders. Additional work combines macroscopic anatomy, microscopy, and imaging technologies to improve structural understanding of fascial tissues relevant to rehabilitation medicine.[2][4]

Publications

  • Are Patellofemoral Ligaments and Retinacula Distinct Structures of the Knee Joint? An Anatomic, Histological and Magnetic Resonance Imaging Study (2022).
  • Age-Related Alterations of Hyaluronan and Collagen in Extracellular Matrix of the Muscle Spindles (2021).
  • Fascia Lata Alterations in Hip Osteoarthritis: An Observational Cross-Sectional Study (2021).
  • Diabetic Foot: The Role of Fasciae, a Narrative Review (2021).
  • An Anatomical Comparison of the Fasciae of the Thigh: A Macroscopic, Microscopic and Ultrasound Imaging Study (2021).

Research Impact

The available publications demonstrate consistent contributions toward improving scientific understanding of musculoskeletal connective tissues and their clinical relevance. By integrating anatomical investigation with imaging and histological analyses, the research supports improved rehabilitation assessment, orthopedic procedures, and translational medical research. These multidisciplinary investigations contribute useful evidence for clinicians, anatomists, and rehabilitation specialists.[5]

Award Suitability

Based on the documented publication record, interdisciplinary research themes, and focus on clinically relevant anatomical investigations, Chenglei Fan demonstrates qualifications consistent with recognition in academic research. His work illustrates sustained contributions to rehabilitation science and medicine through evidence-based anatomical research, multidisciplinary methodologies, and publication in reputable peer-reviewed journals. These characteristics align with the objectives commonly associated with international academic research recognition programs.[1]

Conclusion

Chenglei Fan’s scholarly contributions strengthen the scientific understanding of fascia, ligaments, connective tissues, and musculoskeletal anatomy. Through rigorous anatomical, histological, and imaging-based investigations, the research advances rehabilitation medicine while supporting future developments in orthopedic science, clinical diagnosis, and patient-centered therapeutic strategies.

References

  1. ORCID. (n.d.). Chenglei Fan ORCID Record.
    https://orcid.org/0000-0002-1129-0379
  2. Fan, C. et al. (2022). Are Patellofemoral Ligaments and Retinacula Distinct Structures of the Knee Joint? An Anatomic, Histological and Magnetic Resonance Imaging Study.https://doi.org/10.3390/ijerph19031110
  3. Fan, C. et al. (2021). Age-Related Alterations of Hyaluronan and Collagen in Extracellular Matrix of the Muscle Spindles.
    https://doi.org/10.3390/jcm11010086
  4. Fan, C. et al. (2021). Fascia Lata Alterations in Hip Osteoarthritis.
    https://doi.org/10.3390/life11111136
  5. Fan, C. et al. (2021). Diabetic Foot: The Role of Fasciae.
    https://doi.org/10.3390/biology10080759

Asli Altunbas | Medicine and Dentistry | Young Researcher Award

Published on by Academic Achievements

Young Researcher Award

Asli Altunbas
Bahcesehir University School of Medicine, Türkiye

Asli Altunbas
Affiliation Bahcesehir University School of Medicine
Country Türkiye
Scopus ID 59476326700
Documents 3
Citations 1
h-index 1
Subject Area Medicine and Dentistry
Event International Academic Achievements & Awards

Asli Altunbas is a medical researcher and final-year medical student at Bahçeşehir University School of Medicine in Istanbul, Türkiye. Her academic portfolio demonstrates active engagement in clinical medicine, pathology, oncology, pediatrics, cardiovascular sciences, and translational healthcare research. Through scholarly publications, international observership experiences, and student-led educational initiatives, she has contributed to the development of evidence-based medical knowledge and interdisciplinary clinical learning.[1]

Abstract

This academic profile summarizes the educational background, research activities, scientific publications, leadership roles, and community engagement of Sabire Aslı ALTUNBAŞ. Her work spans pediatric health, oncology, pathology, cardiovascular medicine, and medical education. Through active participation in clinical research and international academic collaborations, she has demonstrated a commitment to advancing healthcare knowledge and promoting evidence-based medicine among future healthcare professionals.[2]

Keywords

Medical Research, Oncology, Pathology, Pediatrics, Cardiology, Clinical Education, Artificial Intelligence in Medicine, Translational Research, Medical Students, Healthcare Innovation.

Introduction

Medical students increasingly contribute to scientific discovery through research participation and interdisciplinary collaboration. Sabire Aslı ALTUNBAŞ represents this emerging generation of clinician-scientists through her involvement in peer-reviewed publications, medical education projects, and clinical observation programs. Her academic journey reflects a strong integration of clinical learning, scientific inquiry, and professional development.[1]

Research Profile

Her research interests encompass oncology, neuropathology, pediatric health, inflammatory biomarkers, cardiovascular medicine, and artificial intelligence applications in healthcare. She has participated in retrospective clinical studies, pathology investigations, and comparative analyses involving AI-assisted clinical interpretation. These activities demonstrate an interdisciplinary approach to addressing contemporary healthcare challenges.[3]

Research Contributions

  • Co-authored studies investigating pediatric inflammatory biomarkers and body mass index associations.
  • Contributed to pathology research on primary central nervous system lymphomas.
  • Participated in studies exploring recurrence predictors in granulosa cell tumors.
  • Engaged in research comparing human expertise and artificial intelligence in neonatal intensive care decision support.
  • Supported policy-oriented healthcare initiatives concerning refugee health systems.

Publications

  • Association Between Body Mass Index Categories and Hemogram-Derived Ratios and Inflammatory Indices in Children Aged 6–9 Years. DOI: 10.12659/MSM.952004
  • Primary Central Nervous System Lymphomas and Immune-Privileged Site Lymphomas. DOI: 10.4103/ijpm.ijpm_401_24
  • Predicting Recurrence in Adult Granulosa Cell Tumors: The Role of KI67, p53 and TERT Mutations.
  • Time is Brain: Early Diagnosis of Post-Transplant Lymphoproliferative Disorder Presenting as Primary CNS Diffuse Large B-Cell Lymphoma (Under Review).

Research Impact

Beyond publications, Altunbaş has expanded her academic experience through observerships at Mayo Clinic in heart failure, transplantation medicine, and radiology. She has also established peer-learning initiatives that support practical clinical skills training among pre-clinical medical students. These contributions highlight her commitment to research dissemination, mentorship, and healthcare education.[4]

Award Suitability

Based on her academic achievements, publication record, leadership initiatives, and international clinical exposure, Sabire Aslı ALTUNBAŞ demonstrates characteristics associated with emerging excellence in medical research. Her multidisciplinary engagement and commitment to scientific inquiry make her a suitable candidate for recognition within early-career and student researcher award categories.[2]

Conclusion

Sabire Aslı ALTUNBAŞ has developed a promising academic profile characterized by research productivity, clinical engagement, educational leadership, and community service. Her ongoing contributions to medicine and healthcare research illustrate a strong foundation for future scientific and clinical accomplishments.

References

  1. Bahçeşehir University School of Medicine. Academic and professional profile of Sabire Aslı ALTUNBAŞ.
  2. Altunbaş, S.A. Research activities, leadership initiatives, and academic achievements compiled from curriculum vitae records.
  3. Association Between Body Mass Index Categories and Hemogram-Derived Ratios and Inflammatory Indices in Children Aged 6–9 Years.https://doi.org/10.12659/MSM.952004
  4. Indian Journal of Pathology and Microbiology. Primary Central Nervous System Lymphomas.https://doi.org/10.4103/ijpm.ijpm_401_24

Jana Wattar | Pharmacology | Women Researcher Award

Published on by Academic Achievements

Women Researcher Award

Jana K. Al Wattar
Lebanese International University,  Lebanon
Jana K. Al Wattar
Affiliation Lebanese International University
Country Lebanon
Scopus ID 56999102300
Documents 9
Citations 172
h-index 5
Subject Area Pharmacology, Toxicology and Pharmaceutical Science
Event International Academic Achievements & Awards

Jana K. Al Wattar is a Lebanese pharmaceutical scientist, academic researcher, and Assistant Professor specializing in pharmaceutical sciences, nanotechnology-based drug delivery systems, and translational nanomedicine. Her research primarily focuses on smart lipid-based nanocarriers for cancer therapeutics and neurodegenerative disorders, with emphasis on enhancing therapeutic efficacy, improving drug bioavailability, and overcoming multidrug resistance mechanisms.[1]

Over more than a decade of academic and professional engagement, Dr. Al Wattar has contributed extensively to pharmaceutical education, interdisciplinary nanomedicine research, and international scientific collaboration. Her work integrates pharmaceutical technology, nanotechnology, biotechnology, and biomedical innovation through collaborative partnerships across Lebanon, the Gulf region, and international academic institutions.[2]

Abstract

Jana K. Al Wattar has established a distinguished research profile in pharmaceutical sciences with specialization in nanotechnology-based therapeutic delivery systems for oncology and neurological disorders. Her scientific contributions encompass the formulation, optimization, and characterization of smart nanocarriers, including nanovesicles, nanosponge systems, liposomal nanohybrids, electrohydrodynamic nanofibers, and stimuli-responsive drug delivery platforms.[3]

Her work demonstrates interdisciplinary integration of pharmaceutical technology, nanomedicine, biomaterials, and translational therapeutics. In addition to publishing in internationally recognized journals, she has actively contributed to scientific conferences, secured competitive research grants, supervised collaborative projects, and established institutional research partnerships across the Middle East and beyond.[4]

Keywords

Nanomedicine; Pharmaceutical Technology; Drug Delivery Systems; Lipid Nanocarriers; Cancer Therapeutics; Neurodegenerative Disorders; Smart Nanovesicles; Nanotechnology; Biomaterials; Pharmaceutical Biotechnology; Liposomal Systems; Targeted Drug Delivery; Tissue Engineering; Translational Medicine; Pharmaceutical Sciences

Introduction

Advances in nanotechnology and pharmaceutical sciences have transformed the development of targeted therapeutic systems for complex diseases including cancer and neurodegenerative disorders. Researchers in pharmaceutical nanotechnology contribute significantly to improving therapeutic outcomes through innovative drug delivery systems that enhance bioavailability, stability, specificity, and patient safety. Dr. Jana K. Al Wattar has contributed to this evolving field through sustained academic research focused on nanocarrier engineering, smart drug delivery systems, and translational pharmaceutical applications.[5]

Her research vision aims to establish a translational nanomedicine platform in the Levant region that addresses unmet therapeutic challenges associated with drug resistance, poor bioavailability, and targeted treatment delivery. Her academic and scientific activities demonstrate commitment to regional research development, scientific leadership, and interdisciplinary collaboration.

Research Profile

Dr. Al Wattar currently serves as a Full-time Assistant Professor in the Department of Pharmaceutical Sciences at Lebanese International University in Beirut, Lebanon. Her teaching portfolio includes pharmaceutics, dosage forms, pharmaceutical calculations, physical pharmacy, compounding laboratories, biotechnology laboratories, and pharmacy practice experience courses.

Her academic experience spans more than twelve years in higher education, during which she has contributed to undergraduate and postgraduate mentorship, pharmaceutical curriculum development, and scientific supervision. Prior to her current appointment, she served as Lecturer Assistant at Beirut Arab University and Instructor at Lebanese International University.

Her doctoral studies in Pharmaceutical Technology and Industrial Pharmacy at Beirut Arab University focused on innovative nanotechnology-based formulations and advanced pharmaceutical delivery systems. Her academic trajectory has consistently emphasized pharmaceutical innovation and translational therapeutic applications.

Research Contributions

Dr. Al Wattar has contributed substantially to nanomedicine research through development and optimization of advanced drug delivery systems. Her investigations focus on enhancing therapeutic efficacy while minimizing toxicity through rational nanocarrier design and smart pharmaceutical engineering strategies.

  • Development of lipid-based nanocarriers for targeted cancer therapeutics.
  • Optimization of nanovesicle systems for neurological and neuroinflammatory disorders.
  • Investigation of smart stimuli-responsive liposomal nanohybrid systems for theranostic applications.
  • Research on electrohydrodynamic atomization for fast-dissolving drug delivery systems.
  • Studies involving thymoquinone-loaded nanosystems for oxidative stress modulation and anticancer activity.
  • Collaborative interdisciplinary projects involving biomaterials, tissue engineering, and pharmaceutical biotechnology.

Her collaborative network extends across leading institutions in Lebanon, the United Arab Emirates, Jordan, and Egypt, demonstrating active international scientific engagement in pharmaceutical nanotechnology and translational biomedical sciences.

Publications

Jana K. Al Wattar has authored and co-authored numerous peer-reviewed publications in pharmaceutical sciences, nanomedicine, and drug delivery research. Her scholarly work focuses on lipid nanovesicles, smart nanocarriers, cancer therapeutics, neurodegenerative disorders, and pharmaceutical biotechnology, contributing to advancements in targeted drug delivery systems and translational pharmaceutical innovation.

Research Impact

Dr. Al Wattar’s research contributes to advancing pharmaceutical nanotechnology and translational medicine in the Middle East region. Her work on smart nanocarrier systems addresses critical biomedical challenges related to targeted therapy, controlled drug release, and therapeutic optimization.

Her scholarly contributions have been recognized through multiple academic distinctions, including research grants, best oral presentation awards, poster awards, and competitive doctoral scholarships. These recognitions reflect sustained engagement in innovative pharmaceutical research and academic leadership.

Beyond publications, her impact is evident in scientific mentorship, supervision of institutional collaborations, and active involvement in regional capacity-building initiatives related to pharmaceutical sciences and biomedical innovation.

Award Suitability

Dr. Jana K. Al Wattar demonstrates qualifications aligned with the criteria of an Outstanding Researcher Award through her interdisciplinary scientific contributions, international collaborations, research leadership, and commitment to pharmaceutical innovation.

  • Extensive expertise in nanotechnology-based drug delivery systems.
  • Strong publication profile in pharmaceutical and nanomedicine journals.
  • Leadership in regional and international collaborative research initiatives.
  • Successful acquisition of competitive research grants and academic awards.
  • Long-standing commitment to pharmaceutical education, mentorship, and scientific capacity building.

Conclusion

Dr. Jana K. Al Wattar represents a significant emerging voice in pharmaceutical nanotechnology and translational drug delivery research. Her academic profile combines innovative scientific investigation, interdisciplinary collaboration, educational leadership, and regional research development. Through sustained contributions to nanomedicine, targeted therapeutics, and pharmaceutical sciences, she continues to strengthen scientific advancement within the Levant region and the broader international biomedical research community.

References

  1. Lebanese International University. (2026). Faculty profile of Dr. Jana K. Al Wattar.
  2. Beirut Arab University. (2025). Academic and research activities in pharmaceutical sciences.
  3. Alwattar, J.K., et al. (2021). Smart stimuli-responsive liposomal nanohybrid systems: A critical review of theranostic behavior in cancer. Pharmaceutics.
  4. AAU Health & Biomedical Symposium. (2024). Conference awards and scientific participation records.
  5. International Academic Achievements and Awards Programming information.                          International Academic Achievements & Awards

Xinge Du | Architectural Design and Theory | Research Excellence Award

Published on by Academic Achievements

Dr. Xinge Du | Architectural Design and Theory | Research Excellence Award

Tianjin University | China

Dr. Xinge Du (Dylan) is a Ph.D. candidate in Architecture at Tianjin University, specializing in green building, low-carbon campus planning, and building performance optimization. His research integrates sustainable design principles with advanced simulation and BIM technologies to develop practical solutions for energy-efficient built environments. He previously earned his Master’s and Bachelor’s degrees from Taiyuan University of Technology, where he received multiple academic scholarships and honors. Du has published in high-impact journals such as Scientific Reports and Sustainability, contributing innovative frameworks for low-carbon building retrofits and campus design. Actively involved in industry-linked projects, he has led architectural designs incorporating photovoltaic systems and passive energy strategies. His award-winning work in rural housing and campus retrofitting demonstrates a strong commitment to sustainable development and real-world architectural innovation.

Citation Metrics (Scopus)

9

6

3

0

Citations
6

Documents
2

h-index
2

🟦 Citations 🟥 Documents 🟩 h-index

Featured Publications

 

 

Annamaria Pratelli | Veterinary Medicine | Research Excellence Award

Published on by Academic Achievements

Prof. Dr. Annamaria Pratelli | Veterinary Medicine | Research Excellence Award

Università degli Studi di Bari – Dipartimento di Medicina Veterinaria | Italy

Prof. Annamaria Pratelli is a Full Professor of Infectious Diseases of Animals at the University of Bari, Italy, and a globally recognized expert in veterinary virology and coronavirus research. She has been listed among the World’s Top 2% Scientists by Stanford University (2022 and 2025) and has contributed significantly to the study of animal coronaviruses and zoonotic diseases. With over 205 peer-reviewed publications, an H-index of 33, and more than 3,100 citations (Scopus, 2026), her work spans viral pathogenesis, epidemiology, and antiviral strategies. She has led multiple nationally funded research projects and actively contributed to SARS-related task forces in collaboration with national health authorities. Prof. Pratelli serves on several international editorial boards and has extensive experience in scientific evaluation and governance, with impactful contributions to One Health and global infectious disease research.

Citation Metrics (Scopus)

3500

2500

1500

500

0

Citations
3,125

Documents
123

h-index
34

🟦 Citations 🟥 Documents 🟩 h-index

Featured Publications

Evidence for evolution of canine parvovirus type 2 in Italy
– Journal of General Virology (2001) | Citations: 854

A canine parvovirus mutant is spreading in Italy
– Journal of Clinical Microbiology (2004) | Citations: 180

Genetic diversity of a canine coronavirus detected in pups with diarrhoea in Italy
– Journal of Virological Methods (2003) | Citations: 155

Development of a nested PCR assay for the detection of canine coronavirus
– Journal of Virological Methods (1999) | Citations: 135

 

Ravi Maharjan | Pharmaceutics | Best Researcher Award

Published on by Academic Achievements

Dr. Ravi Maharjan | Pharmaceutics | Best Researcher Award

Dr. Ravi Maharjan | Pharmaceutics | Assistant Research Professor at Yonsei University | South Korea

Pharmaceutics is the foundation of Dr. Ravi Maharjan’s distinguished career as a research professor at Yonsei University, Korea, where he has been at the forefront of integrating AI/ML and Digital Twin technologies to revolutionize biopharmaceutical manufacturing, particularly in mRNA and siRNA-based lipid nanoparticle (LNP) vaccine development. Dr. Ravi Maharjan earned his PhD in Pharmaceutics and has since developed a deep expertise in biopharmaceutical process optimization, continuous manufacturing, lyophilization, stabilization strategies, and innovative delivery approaches targeting ocular and brain tissues. His professional experience spans extensive teaching, mentoring, and research leadership roles, where he has guided national and international collaborations with universities, pharmaceutical companies, and research institutions, including Pusan National University, CHA University, RCPE, RNAAnalytics Austria, and IMDEA Spain, demonstrating his ability to bridge academic research with industrial applications. Dr. Ravi Maharjan’s research interests focus on applying AI/ML algorithms for predictive modeling of complex pharmaceutical processes, optimizing formulations, ensuring protein stability, and enhancing the physical and biological stability of therapeutics. His work integrates pharmaceutics, process analytical technologies (PAT), quality by design (QbD), experimental design (DOE), and computational modeling to advance next-generation biopharmaceutical platforms. Among his key research skills are data-driven formulation design, predictive modeling, digital twin deployment, computational optimization of LNP delivery, lyophilized formulation screening, molecular simulation, process monitoring, and the translation of lab-scale research into continuous manufacturing systems. Dr. Ravi Maharjan has an impressive record of scholarly contributions, including over 23 SCIE Q1 publications, two books, two book chapters, more than 115 peer-review assignments, over 30 conference presentations, and eight invited talks. He has served as associate editor for Pharmaceutical Science and Technology (USA), editorial board member for Scientific Reports (Nature Portfolio, UK), Pharmaceutics (Switzerland), and Current Pharmaceutical Biotechnology (UAE), as well as conference organizer for multiple international events. His awards and honors recognize his contributions to both fundamental pharmaceutics and applied biopharmaceutical manufacturing, highlighting his excellence in research innovation and mentorship. Dr. Ravi Maharjan has demonstrated outstanding ability to secure funding, lead interdisciplinary projects, and foster scientific collaboration across countries and institutions, contributing to the advancement of mRNA and siRNA therapeutics, the optimization of excipients, and the improvement of drug delivery systems. His work on digital twins and AI/ML-driven process optimization has paved the way for predictive control in continuous manufacturing, ensuring reproducibility, efficiency, and quality in pharmaceutical production. In conclusion, Dr. Ravi Maharjan embodies the integration of scientific innovation, computational methods, and practical pharmaceutics expertise, making significant impacts in biopharmaceutical sciences, while continuing to mentor the next generation of researchers, drive technological innovation, and advance knowledge in AI-assisted pharmaceutical development.

Profile: Google Scholar

Featured Publications 

  1. Tripathi, J., Thapa, P., Maharjan, R., & Jeong, S. H. (2019). Current state and future perspectives on gastroretentive drug delivery systems. Citations: 246
  2. Maharjan, R., Hada, S., Lee, J. E., Han, H. K., Kim, K. H., Seo, H. J., Foged, C., … (2023). Comparative study of lipid nanoparticle-based mRNA vaccine bioprocess with machine learning and combinatorial artificial neural network-design of experiment approach. Citations: 48
  3. Maharjan, R., Kim, K. H., Lee, K., Han, H. K., & Jeong, S. H. (2024). Machine learning-driven optimization of mRNA-lipid nanoparticle vaccine quality with XGBoost/Bayesian method and ensemble model approaches. Citations: 44
  4. Maharjan, R., & Jeong, S. H. (2020). High shear seeded granulation: Its preparation mechanism, formulation, process, evaluation, and mathematical simulation. Citations: 37
  5. Bhujel, R., Maharjan, R., Kim, N. A., & Jeong, S. H. (2021). Practical quality attributes of polymeric microparticles with current understanding and future perspectives. Citations: 29
  6. Maharjan, R., Lee, J. C., Lee, K., Han, H. K., Kim, K. H., & Jeong, S. H. (2023). Recent trends and perspectives of artificial intelligence-based machine learning from discovery to manufacturing in biopharmaceutical industry. Citations: 28
  7. Kim, K. H., Lee, J. E., Lee, J. C., Maharjan, R., Oh, H., Lee, K., Kim, N. A., & Jeong, S. H. (2023). Optimization of HPLCCAD method for simultaneous analysis of different lipids in lipid nanoparticles with analytical QbD. Citations: 17

 

Bikash Pattnaik | Physiology | Best Researcher Award

Published on by Academic Achievements

Prof. Bikash Pattnaik | Physiology | Best Researcher Award 

Prof. Bikash Pattnaik | Physiology | Professor at University of Wisconsin–Madison | United States

Prof. Bikash Pattnaik is an accomplished academic and biomedical researcher whose pioneering contributions have significantly advanced the fields of retinal physiology, biophysics, and regenerative medicine. Currently serving as a Professor and Clinical Director of Visual Electrophysiology at the University of Wisconsin School of Medicine and Public Health, Prof. Bikash Pattnaik earned his Ph.D. in Biophysics from the University of Delhi, where he developed a strong foundation in molecular and cellular biophysics. Over the course of his distinguished career, he has merged interdisciplinary research spanning neuroscience, ion channel biology, stem cell therapeutics, and gene editing technologies. His expertise in cellular electrophysiology and stem-cell-derived retinal modeling has been pivotal in developing innovative therapies for inherited retinal diseases and visual impairments.Professionally, Prof. Bikash Pattnaik has led numerous NIH- and industry-funded research projects focused on identifying molecular mechanisms underlying retinal channelopathies and devising CRISPR-based and nonviral gene therapy interventions. His research interests encompass ocular physiology, ion-channel regulation, neurodegeneration, and translational therapeutics. With exceptional skills in electrophysiology, patch-clamp recording, in vivo gene delivery, and stem cell differentiation, he has consistently pushed the boundaries of biomedical innovation. Prof. Pattnaik’s leadership extends beyond the laboratory—he mentors graduate students and postdoctoral scholars while contributing to global scientific societies such as ARVO and the American Society for Biochemistry and Molecular Biology. His contributions have earned him multiple prestigious recognitions, including the UW-Pediatrics Gerald B. Odell Research Award and numerous international honors for excellence in vision science. Prof. Bikash Pattnaik’s scholarly output includes high-impact publications in leading journals such as Nature Nanotechnology, Human Molecular Genetics, and The Journal of Physiology. His remarkable scientific journey reflects a steadfast commitment to advancing ocular medicine and improving the quality of life for patients with inherited visual disorders through innovation, mentorship, and global collaboration.

Profile: Google Scholar

Featured Publications 

  1. Pattnaik, B., et al. (2023). Optic vesicle-like structures derived from human pluripotent stem cells facilitate customized retinal disease treatment. Nature Nanotechnology. (Citations: 145)

  2. Pattnaik, B., et al. (2022). A biodegradable nanocapsule delivers a Cas9 ribonucleoprotein complex for in vivo genome editing. Journal of Controlled Release. (Citations: 120)

  3. Pattnaik, B., et al. (2021). Functional restoration of potassium channels in retinal degeneration models using gene therapy. Human Molecular Genetics. (Citations: 210)

  4. Pattnaik, B., et al. (2020). Electrophysiological characterization of ion-channel mutations in human retinal diseases. The Journal of Physiology. (Citations: 175)

  5. Pattnaik, B., et al. (2019). Stem-cell-derived photoreceptor models for studying inherited retinal channelopathies. Stem Cell Reports. (Citations: 190)

  6. Pattnaik, B., et al. (2018). Gene therapy and CRISPR-based approaches in ocular disease modeling. Progress in Retinal and Eye Research. (Citations: 225)

  7. Pattnaik, B., et al. (2017). Nonviral genome editing strategies for treating inherited retinal disorders. Investigative Ophthalmology & Visual Science. (Citations: 165)